Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:26 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 3,139 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo solution Clear all
Completed Not applicable Interventional Results available

Efficacy of Tranexamic Acid for Reducing Blood Loss and Blood Transfusion After Periacetabular Osteotomy

NCT02253810
View directory record Official record
Conditions
Dysplasia, Congenital Hip
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
12 Years to 45 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

EPOgen and Restrictive Transfusions in Patients Undergoing Cardiac Surgery (EPORT)

NCT02802592
View directory record Official record
Conditions
Cardiac Surgery-CABG, Cardiac Valve Replacement
Interventions
Epogen, Normal Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 64 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 29, 2026, 6:26 AM EDT
Withdrawn Not applicable Interventional

Does Dexamethasone Administration Improve Recovery In Patients Undergoing Minimally Invasive Sacrocolpopexy?

NCT03094442
View directory record Official record
Conditions
Quality of Life, Pelvic Organ Prolapse, Prolapses, Vaginal Vault
Interventions
Dexamethasone, Normal saline
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional

Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19

NCT04410354
View directory record Official record
Conditions
COVID-19
Interventions
Merimepodib, Matching Placebo, Remdesivir
Drug
Lead sponsor
ViralClear Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
10
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional

Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)

NCT07220629
View directory record Official record
Conditions
Obesity
Interventions
NT-0796, Placebo
Drug
Lead sponsor
Rezera (formerly NodThera Limited)
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Mesa, Arizona • Hialeah, Florida • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Early Phase 1 Interventional

Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System

NCT04521569
View directory record Official record
Conditions
Lung Transplant
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 75 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 29, 2026, 6:26 AM EDT
Not listed Phase 2 Interventional

A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

NCT06296966
View directory record Official record
Conditions
Dry Eye
Interventions
VSJ-110, Placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 6, 2024 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 2 Interventional Results available

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

NCT04059094
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
BI 1265162, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
12 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
8
States / cities
Orlando, Florida • Indianapolis, Indiana • Chapel Hill, North Carolina + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2021 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

A Phase IIa Study to Investigate the Efficacy and Safety of AZD7624 in Chronic Obstructive Pulmonary Disease (COPD) Patients While on Maintenance Therapy

NCT02238483
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease COPD
Interventions
AZD7624 1.0 mg, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Adenoviral Conjunctivitis With SHP640 Compared to Placebo

NCT02998554
View directory record Official record
Conditions
Adenoviral Conjunctivitis
Interventions
SHP640, Placebo
Drug
Lead sponsor
Shire
Industry
Eligibility
Not listed
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
29
States / cities
Glendale, California • Los Angeles, California • Torrance, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Early Phase 1 Interventional

Blood Pressure Lowering Effects of Angiotensin-(1-7) in Primary Autonomic Failure

NCT02591173
View directory record Official record
Conditions
Autonomic Nervous System Disorders, Pure Autonomic Failure, Shy-Drager Syndrome, Orthostatic Hypotension, Dysautonomic
Interventions
Angiotensin-(1-7), Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 12, 2021 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Not applicable Interventional Results available

Post-op Acetaminophen vs NSAID Use on Lumbar Spinal Fusion Outcomes

NCT02700451
View directory record Official record
Conditions
Lumbar Osteoarthritis, Spondylosis, Lumbar Disc Disease, Spinal Stenosis
Interventions
Ketorolac, Acetaminophen, Placebo
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Results available

Ketamine-assisted Therapy for Advanced GI Cancer

NCT06077487
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization
Interventions
Ketamine, Ketamine Injectable Product, Meaning and Purpose therapy, Placebo, Questionnaires
Drug · Behavioral · Other
Lead sponsor
Brian Anderson, MD
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

NCT04032093
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV vaccine, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
1,153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
145
States / cities
Birmingham, Alabama • Cullman, Alabama • Glendale, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Results available

AZD8601 Study in CABG Patients

NCT03370887
View directory record Official record
Conditions
Heart Failure
Interventions
AZD8601, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 10, 2024 · Synced Oct 29, 2026, 6:26 AM EDT
Withdrawn Phase 2 Interventional

Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery

NCT03446599
View directory record Official record
Conditions
Vasoplegia, Hypotension, Coronary Artery Disease, Cardiac Valve Disease
Interventions
Hydroxocobalamin, Methylene Blue, Normal saline
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 2, 2020 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Study of OnabotulinumtoxinA in Upper Facial Rhytides

NCT02261493
View directory record Official record
Conditions
Facial Rhytides, Glabellar Rhytides
Interventions
OnabotulinumtoxinA, Normal Saline
Biological · Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
787 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Newport Beach, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 29, 2026, 6:26 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Effects of Creatine and Carbohydrate Supplementation on Endurance Performance

NCT07712653
View directory record Official record
Conditions
Exercise Performance Recovery
Interventions
Creatine Monohydrate, Carbohydrate, Creatine Monohydrate and Carbohydrate, placebo solution
Dietary Supplement
Lead sponsor
California Polytechnic State University-San Luis Obispo
Other
Eligibility
18 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Luis Obispo, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Not yet recruiting Phase 2 Interventional

Evaluation of Pain Management After Surgery When Using Nerve Blocks in the Pediatric Population

NCT06559137
View directory record Official record
Conditions
Anterior Cruciate Ligament (ACL) Tear, Sports Injuries in Children, Analgesia, Pain, Postoperative
Interventions
Ropivacaine 0.2% Injectable Solution
Drug
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
13 Years to 21 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Frisco, Texas
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Phase II Safety and Acceptability of an Investigational Injectable Product, TMC278LA, for Pre-Exposure Prophylaxis

NCT02165202
View directory record Official record
Conditions
Human Immunodeficiency Virus (HIV)
Interventions
Rilpivirine, Placebo
Drug
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Newark, New Jersey • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 29, 2026, 6:26 AM EDT
Recruiting Phase 3 Interventional

Study of IV Human Plasma-derived C1 Esterase Inhibitor Concentrate in Patients With Congenital C1-INH Deficiency for Treatment and Pre-procedure Preventing of Acute Hereditary Angioedema Attacks

NCT06361537
View directory record Official record
Conditions
Acute Hereditary Angio Edema
Interventions
OCTA-C1-INH, Placebo
Drug · Other
Lead sponsor
Octapharma
Industry
Eligibility
2 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Centennial, Colorado • Farmington Hills, Michigan • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 6:26 AM EDT
Terminated Phase 4 Interventional Results available

Inflammation-Induced CNS Glutamate Changes in Depression

NCT03004443
View directory record Official record
Conditions
Depression
Interventions
Infliximab, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 29, 2026, 6:26 AM EDT
Completed Phase 4 Interventional Results available

SIMBRINZA® Suspension BID as an Adjunctive to Prostaglandin Analogue (PGA)

NCT02419508
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension, Brinz/brim vehicle, Prostaglandin analogue
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 29, 2026, 6:26 AM EDT